# Autolus Therapeutics plc: overview AUTL · Nasdaq · CIK 1730463 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/autl.md) · [Financials](/companies/autl/financials.md) · [Filings](/companies/autl/filings.md) · [Insiders](/companies/autl/insiders.md) Latest reported revenue: [$45.7m](/filings/0001730463-26-000123.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001730463-26-000123). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001730463-25-000088.md) | [0.0 d](/filings/0001730463-26-000038.md) | [9.0](/filings/0001730463-26-000065.md) | [20.9](/filings/0001730463-26-000123.md) | [21.2](/filings/0001730463-25-000088.md) | [24.3 d](/filings/0001730463-26-000038.md) | [26.2](/filings/0001730463-26-000065.md) | [45.7](/filings/0001730463-26-000123.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(261600.0%) d](/filings/0001730463-26-000038.md) | [(726.3%)](/filings/0001730463-26-000065.md) | [(292.6%)](/filings/0001730463-26-000123.md) | [(337.9%)](/filings/0001730463-25-000088.md) | [(298.3%) d](/filings/0001730463-26-000038.md) | [(227.0%)](/filings/0001730463-26-000065.md) | [(95.9%)](/filings/0001730463-26-000123.md) | | Net margin | % | not reported | [(95193.1%) d](/filings/0001730463-26-000038.md) | [(781.1%)](/filings/0001730463-26-000123.md) | [(229.0%)](/filings/0001730463-26-000123.md) | [(373.3%)](/filings/0001730463-25-000088.md) | [(371.9%) d](/filings/0001730463-26-000038.md) | [(273.1%)](/filings/0001730463-26-000123.md) | [(85.6%)](/filings/0001730463-26-000123.md) | | Diluted EPS | $ per share | [(0.31)](/filings/0001730463-25-000088.md) | not reported | [(0.26)](/filings/0001730463-26-000065.md) | [(0.18)](/filings/0001730463-26-000123.md) | [(0.30)](/filings/0001730463-25-000088.md) | not reported | [(0.27)](/filings/0001730463-26-000065.md) | [(0.15)](/filings/0001730463-26-000123.md) | | Free cash flow | $m | [(86.3) d](/filings/0001730463-25-000088.md) | [(49.0) d](/filings/0001730463-26-000038.md) | [(83.8)](/filings/0001730463-26-000065.md) | [(80.1) d](/filings/0001730463-26-000123.md) | [(72.3) d](/filings/0001730463-25-000088.md) | [(68.2) d](/filings/0001730463-26-000038.md) | [(68.0)](/filings/0001730463-26-000065.md) | [(26.0) d](/filings/0001730463-26-000123.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [1.7](/filings/0001730463-25-000019.md) | [10.1](/filings/0001730463-26-000038.md) | [75.4](/filings/0001730463-26-000038.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(10583.1%)](/filings/0001730463-25-000019.md) | [(2385.6%)](/filings/0001730463-26-000038.md) | [(358.9%)](/filings/0001730463-26-000038.md) | | Net margin | % | not reported | not reported | [(12272.3%)](/filings/0001730463-25-000019.md) | [(2180.5%)](/filings/0001730463-26-000038.md) | [(381.4%)](/filings/0001730463-26-000038.md) | | Diluted EPS | $ per share | [(1.97)](/filings/0001730463-24-000048.md) | [(1.57)](/filings/0001730463-24-000048.md) | [(1.20)](/filings/0001730463-25-000019.md) | [(0.86)](/filings/0001730463-26-000038.md) | [(1.08)](/filings/0001730463-26-000038.md) | | Free cash flow | $m | [(127)](/filings/0001730463-24-000048.md) | [(123)](/filings/0001730463-24-000048.md) | [(157)](/filings/0001730463-25-000019.md) | [(228)](/filings/0001730463-26-000038.md) | [(303)](/filings/0001730463-26-000038.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/autl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MAK CAPITAL ONE LLC](/funds/1385702.md) | 2026-06-30 | $53.8m | 33,621,487 | | Unchanged | | [Blackstone Inc.](/funds/1393818.md) | 2026-06-30 | $32.8m | 20,485,611 | | Unchanged | | [Syncona Portfolio Ltd](/funds/1725042.md) | 2026-06-30 | $26.6m | 16,640,720 | | Unchanged | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $24.0m | 15,000,000 | | Reduced −800,000 | | [Tetragon Partners GP Ltd](/funds/1515070.md) | 2026-06-30 | $15.2m | 9,500,000 | | Unchanged | | [SCHRODER INVESTMENT MANAGEMENT GROUP](/funds/1086619.md) | 2026-06-30 | $12.9m | 7,833,282 | | Reduced −1,656,063 | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $7.1m | 4,447,910 | | Unchanged | | [BNP PARIBAS ASSET MANAGEMENT Holding S.A.](/funds/1520354.md) | 2026-06-30 | $5.4m | 3,361,156 | | Unchanged | | [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $5.3m | 3,316,626 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.2m | 1,984,700 | | Reduced −314,799 | ## Recent filings [All 328 filings](/companies/autl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-28 | 21:08 ET | [SCHEDULE 13D/A](/filings/0001213900-26-095283.md) | Ownership report, active investor, amended | 0001213900-26-095283 | | 2026-08-11 | 16:13 ET | [10-Q](/filings/0001730463-26-000123.md) | Quarterly report, period 2026-06-30 | 0001730463-26-000123 | | 2026-08-11 | 07:33 ET | [8-K](/filings/0001730463-26-000119.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001730463-26-000119 | | 2026-08-03 | 08:11 ET | [8-K](/filings/0001730463-26-000112.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001730463-26-000112 | | 2026-08-03 | 07:00 ET | [8-K](/filings/0001193125-26-329526.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-329526 | | 2026-06-29 | 16:03 ET | [8-K](/filings/0001730463-26-000072.md) | 5.07 Shareholder vote results | 0001730463-26-000072 | | 2026-06-09 | 07:30 ET | [8-K](/filings/0001730463-26-000069.md) | 8.01 Other events | 0001730463-26-000069 | | 2026-05-14 | 16:31 ET | [10-Q](/filings/0001730463-26-000065.md) | Quarterly report, period 2026-03-31 | 0001730463-26-000065 | | 2026-05-14 | 07:53 ET | [8-K](/filings/0001730463-26-000058.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001730463-26-000058 | | 2026-04-29 | 17:28 ET | [8-K](/filings/0001193125-26-192362.md) | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-192362 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001730463-26-000038.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/226f6570-2c2d-4226-95e5-94ae2aac9f02) ## About the filer - CIK: 1730463 - Tickers: AUTL - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: X0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.